Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Drug Treats ‘Water Intoxication’ Faster, More Effectively
Uncategorized

Drug Treats ‘Water Intoxication’ Faster, More Effectively

By medwebNov 1, 2006
Share
Facebook Twitter Email

November 14, 2006

Contact: Marla Paul at (312) 503-8928 or at
marla-paul@northwestern.edu

Drug Treats ‘Water Intoxication’ Faster, More Effectively

CHICAGO—Results of the two largest studies on hyponatremia, SALT-1 and SALT-2, presented November 14 at the American Heart Association’s Scientific Sessions in Chicago, found that the investigational drug tolvaptan treated hyponatremia—water intoxication—faster and more effectively than available treatments.

“These studies proved for the first time that hyponatremia, which is associated with poor outcomes, can be treated effectively with an oral drug that has no significant side effects,” said Mihai Gheorghiade, MD, professor of medicine at Northwestern University’s Feinberg School of Medicine and a cardiologist at Northwestern Memorial Hospital, who presented the results of the studies at the AHA meeting.

Hyponatremia is a relatively common electrolyte disorder. It affects a wide spectrum of patients including those with liver problems and heart failure and the elderly. It also may affect marathon runners.

Occurring in 15 to 20 percent of hospitalized patients with heart failure, hyponatremia is the opposite of dehydration. Known as “water intoxication,” the condition occurs when serum sodium concentration in the blood falls to dangerously low levels causing cells in the body to stop excreting water. Normal serum sodium levels are between 135 and 145 millimoles per liter (mmol/L). Hyponatremia occurs when serum concentration drops to less than 135 mmol/L. In severe cases, it can lead to cerebral edema and even death.

Yet current therapies for hyponatremia are often ineffective and poorly tolerated. The two SALT studies will be published in the November 16 issue of the New England Journal of Medicine offer promising information.

Robert Schrier, MD, professor of medicine at the University of Colorado, Denver, and Dr. Gheorghiade and their colleagues at other institutions, found that tolvaptan, a V2-receptor antagonist developed by Otsuka Pharmaceutical Co., Ltd. and Otsuka Maryland Research Institute, Inc., began to improve patients’ serum sodium levels almost immediately.

“This easy-to-administer oral drug begins to normalize serum sodium within hours. The normalization is sustained during long-term therapy,” Dr. Gheorghiade said. “It is also important to note that tolvaptan was associated with an improvement in mental performance. This is important since cognition can decrease as a result of low serum sodium.”

The SALT-1 and SALT-2 studies (Sodium Assessment with Increasing Levels of Tolvaptan) looked at 443 patients in the United States and several international sites. During the trial, about half the patients were put on the tolvaptan regimen, the other half on placebo. In both studies, patients assigned to tolvaptan had higher serum sodium concentrations at day 4 and day 30 than those in the placebo group. During the week after discontinuing the tolvaptan, hyponatremia recurred in patients.

SALT-1 and SALT-2 were identical prospective, multicenter, randomized, double-blind placebo-controlled efficacy studies. SALT-1 was conducted at 42 sites in the United States, SALT-2 at 50 international sites.

Research was funded by Otsuka Pharmaceutical Co., Ltd., and Otsuka Maryland Research Institute, Inc.

Share. Facebook Twitter Email

Related Posts

Lurie Cancer Center Receives Merit Extension from NCI

Oct 20, 2021

Drug Combination May Reduce Risk of Leukemia Relapse

Mar 26, 2020

Rewriting the Role of a Transcription Factor

Mar 19, 2020

Comments are closed.

Latest News

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023

Humans are Not Just Big Mice: Identifying Science’s Muscle-Scaling Problem

Mar 20, 2023

AOA Honors New Members

Mar 20, 2023

Celebrating Feinberg’s 2023 Match Day

Mar 17, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230315_NM036
20230315_NM046
20230315_NM134
20230315_NM205
20230315_NM206
20230315_NM132
20230315_NM130
20230315_NM082
20230315_NM063
20230315_NM058
20230315_NM030
20230315_NM038

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.